Trial Condition(s):

Bioequivalence

To establish the bioequivalence between riociguat tablet 1.0 mg intended to be marketed (# 502) and riociguat tablet 1.0 mg used for clinical samples (#512) in Japanese healthy adult male subjects

Bayer Identifier:

14845

ClinicalTrials.gov Identifier:

Not Available

EudraCT Number:

Not Available

Study Completed

Trial Purpose

Please see attached Study Results Summary below.

Inclusion Criteria
No Inclusion Criteria Available
Exclusion Criteria
No Exclusion Criteria Available

Trial Summary

Enrollment Goal
24
Trial Dates
black-arrow
Phase
1
Could I receive a placebo?
No
Products
Adempas (Riociguat, BAY63-2521)
Accepts Healthy Volunteers
N/A

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Osaka Pharmacology Clinical Research Hospital

Osaka, Japan, 532-0003

Status
Completed
 

For details, please refer to trial results

Additional Information